ARIH1 and prostate carcinoma: ARI, androgen receptor inhibitors; CTC, circulating tumor cell; EMT, epithelial to mesenchymal transition; mCRPC, metastatic castration‐resistant prostate cancer; NE, neuroendocrine; NEPC, NE prostate cancer; PCa, prostate cancer.